Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

NCT07746388 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT07746388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07746388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2031
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, nsclc stage ii, nsclc stage iiib, nsclc, stage iii, resectable lung non-small cell carcinoma